Prognostic indicators in male breast carcinoma

Breast Journal

Volumn 4, Issue 4, 1998, Pages 261-269

  Moore, Janet ^a   Friedman, Michael I ^b   Gansler, Ted ^a   Gramlich, Terry L ^c   DeRose, Patricia B ^a   Hunt, Dirk ^a   Cohen, Cynthia ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Male breast carcinoma; Prognostic markers

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; STREPTAVIDIN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MALE BREAST; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031819155     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.440261.x     Document Type: Article

References (57)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. McLachlan S, Erlichman C, Liu F, Miller N, Pintilie M. Male breast cancer: An 11 year review of 66 patients. Breast Cancer Res Treat 1996;40:225-30.
3. Levi F, Randimbison L, La Vecchia C. Breast cancer survival in relation to sex and age. Oncology 1992;49:413-17.
4. Ciattto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of a multicenter series of 150 cases. Tumori 1990;76:555-58.
5. Crichlow RW, Gait SW. Male breast cancer. Surg Clin N Am 1990;70:1165-77.
6. Joshi MG, Lee AKC, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996;77:490-98.
7. Tavassoli FA. General considerations. In: Tavassoli FA, ed. Pathology of the Breast. Norwalk, CT: Appleton and Lange, 1994:25-62.
8. Bacus SS, Ruby SG. Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma. Pathol Annu 1993;28:179-204.
9. DeCresce R. The CAS 100: a computerized microscope image analysis system. Lab Med 1986;17:163-65.
10. Baddoura FK, Cohen C, Unger ER, DeRose PB, Chenggis M. Image analysis for quantitation of estrogen receptor in formalin-fixed paraffin-embedded sections of breast carcinoma. Mod Pathol 1991;4:91-95.
11. Donegan WL. Cancer of the breast in men. CA Cancer J Clin 1991;41:339-54.
12. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992;5:621-25.
13. Hecht JR, Winchester DJ. Male breast cancer. Am J Clin Pathol 1994;102(suppl. 1):S25-S30.
14. Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 1993;24:148-51.
15. 0 breast carcinoma. Am J Surg Pathol 1994;18:158-66.
16. Sahin AA, Sneige M, Ordonez NG, et al. Immunohistochemical assessment of cathepsin D in stages I and II node-negative breast cancer. Appl Immunohistochem 1994;2:15-21.
17. Wagner JL, Thomas CR Jr, Koh W, Rudolph RH. Carcinoma of the male breast: Update 1994. Med Pediatr Oncol 1995;24:123-32.
18. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88-92.
19. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of erbB2 in human breast cancer; impact of fixation. J Pathol 1994;173:65-75.
20. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-18.
21. Schmitt FC, Figueiredo P, Lacerda M. Expression of c-erbB-2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med 1995;119:815-20.
22. Elledge RM, Clark GM, Fugua SAW, Yu Y, Allred DG. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 1994;54:3752-57.
23. Visscher DW, Zarbo RJ, Greenawald KA, Crissman JD. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. In: Rosen, PP., Fechner RE, eds. Pathology Annual, part I, vol. 25. Norwalk, CT: Appleton and Lange 1990:171-210.
24. Pich A, Margaria E, Chiusa L, Ponti R, Geuna M. In male breast carcinoma DNA flow cytometric ploidy correlates with proliferative activity and prognosis [abstract]. Pathol Res Pract 1995;191:754.
25. Schmitt FC, Pereira EM, Andrade LM, Torresan M, de Lucca L. The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor immunoreactivity. Pathol Res Pract 1994;190:786-91.
26. Siitonen SM, Kallioniemi O, Isola JJ. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol 1993;142:1081-89.
27. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992;117:771-77.
28. Ribeiro G. Male breast carcinoma - review of 301 cases from the Christie Hospital and Holt Radium Institute, Manchester. Br J Cancer 1985;51:115-19.
29. Payne S, Bruce DM, Heys SD, Eremin O, Miller ID. Prognostic parameters in male breast cancer [abstract]. J Pathol 1995;175(suppl.):143A.
30. Gattuso P, Reddy VB, Green LK, Castelli MJ, Wick MR. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol 1995;2:199-206.
31. Ruff SJ, Bauer JE, Keenan EJ, Moseley HS, Fletcher WS. Hormone receptors in male breast carcinoma. J Surg Oncol 1981;22:55-59.
32. Fox SB, Rogers S, Day CA, Underwood JCE. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 1992;166:13-18.
33. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Schwartz MK, Urban JA. Estrogen receptor protein in lesions of the male breast. A preliminary report. Cancer 1976;37:1866-68.
34. Davis SL, Barse F, Meoli FG. Male breast carcinoma: clinical experience in a suburban community. J Am Osteopath Assoc 1992;92:1005-6, 1013-16.
35. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochem-istry in male and female breast carcinomas. Eur J Cancer 1996; 32A:1686-92.
36. Lobaccaro J, Lumbroso S, Belon C, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Gen 1993;11:1799-802.
37. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
38. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentration of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989;46:6008-14.
39. Fox SB, Day CA, Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol 1991; 44:960-61.
40. Yeldandi AV, Hussong J, Rao MS. An immunohistochemical analysis of male breast carcinomas for p53 mutation and c-erbB2 overexpression [abstract]. J Histochem Cytochem 1996;44:792.
41. Bobrow LG, Happerfield LC, Millis RR. Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein. Appl Immunohistochem 1996;4:128-34.
42. Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992;23:1141-50.
43. Taylor CR, Shi S, Cote RJ. Antigen retrieval for immunohistochemistry. Status and need for greater standardization. Appl Immunohistochem 1996;4:144-66.
44. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166-76.
45. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
46. Anelli A, Anelli TFM, Youngson B, Rosen PP, Borgen PI. Mutations of the p53 gene in male breast cancer. Cancer 1995;75:2233-38.
47. Dawson PJ, Schroer KR, Wolman SR. ras and p53 genes in male breast cancer. Mod Pathol 1996;9:367-70.
48. Linden MD, Nathanson SD, Zarbo RJ. Evaluation of anti-p53 antibody staining. Quality control and technical considerations. Appl Immunohistochem 1994;2:218-24.
49. Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
50. Wolman SR, Sanford J, Ratner S, Dawson PJ. Breast cancer in males: DNA content and sex chromosome constitution. Mod Pathol 1995;8:239-43.
51. Gattuso P, Reddy VB, Green L, Castelli M, Haley D, Herman C. Prognostic significance of DNA ploidy in male breast carcinoma. A retrospective analysis of 32 cases. Cancer 1992;70:777-80.
52. Hatschek T, Wingren S, Carstensen J, Hultborn R. DNA content and s-phase fraction in male breast carcinomas. Acta Oncol 1994;33:609-13.
53. Tahan SR, Wei Y, Ling P, Bistrian BR. Influence of formalin fixation time and tissue processing method on immunoreactivity of monoclonal antibody PC10 for proliferating cell nuclear antigen. Mod Pathol 1995;8:177-82.
54. Burford-Mason AP, Mackay AJ, Cummins M, Dardick I. Detection of proliferating cell nuclear antigen in paraffin-embedded specimens is dependent on pre-embedding tissue handling and fixation. Arch Pathol Lab Med 1994;118: 1007-13.
55. Dervan PA, Magee HM, Buckley C, Carney DN. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 1992;97(suppl. 1):S21-S28.
56. Guinee W, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993;71: 154-61.
57. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68:2142-49.